Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508653 | 0.81 | TSHR (0.67) | TSHRALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL10401979 | 0.79 | TSHR (0.64) | TSHRALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL2687146 | 0.78 | TSHR (0.56) | TSHRALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL7213624 | 0.78 | IDO1 (0.48) | SMN1; SMN2CA1CA2CA9LMNA | |
| SCHEMBL9411326 | 0.78 | CA1 (0.46) | TSHRALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL470893 | 0.77 | TSHR (0.61) | TSHRALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL5797457 | 0.77 | TSHR (0.61) | TSHRALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL1863832 | 0.77 | TSHR (0.61) | TSHRALDH1A1SMN1; SMN2CA1CA2 | |
| SCHEMBL5311581 | 0.77 | TSHR (1.00) | TSHRALDH1A1CA1CA2CA9 | |
| SCHEMBL27380 | 0.77 | TSHR (1.00) | TSHRALDH1A1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084725-A | 1-Cyano 2-hydroxy compound and preparation method thereof | 南京工业大学 | 2024-05-28 | — | — | CN | claimed |
| US-20230140861-A1 | CROSSLINKING LIGAND, METHOD FOR PATTERNING NANOPARTICLE LAYER, QUANTUM DOT LIGHT-EMITTING DEVICE, AND DISPLAY DEVICE | Beijing Boe Technology Development Co., Ltd. (CN) | 2023-05-11 | — | — | US | claimed |
| CN-114933620-A | Azithromycin derivatives having epithelial barrier enhancing properties | 艾比恩多制药有限责任公司 | 2022-08-23 | — | — | CN | claimed |
| US-20220106349-A1 | Compounds | EPIENDO PHARMACEUTICALS EHF (IS) | 2022-04-07 | — | — | US | claimed |
| US-11236120-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | EPIENDO PHARMACEUTICALS EHF (IS) | 2022-02-01 | — | — | US | claimed |
| CN-113292463-A | Cross-linked ligand, method for patterning nanoparticle layer, quantum dot light-emitting device and display device | 京东方科技集团股份有限公司 | 2021-08-24 | — | — | CN | claimed |
| US-20200317710-A1 | Azithromycin Derivatives With Epithelial Barrier Enhancement Properties | EPIENDO PHARMACEUTICALS EHF (IS) | 2020-10-08 | — | — | US | claimed |
| EP-3708573-A1 | AZITHROMYCIN DERIVATIVES WITH EPITHELIAL BARRIER ENHANCEMENT PROPERTIES | EpiEndo Pharmaceuticals ehf. (IS) | 2020-09-16 | — | — | EP | claimed |
| US-10723752-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | EPIENDO PHARMACEUTICALS EHF (IS) | 2020-07-28 | — | — | US | claimed |
| EP-3377511-B1 | AZITHROMYCIN DERIVATIVES WITH EPITHELIAL BARRIER ENHANCEMENT PROPERTIES | EPIENDO PHARMACEUTICALS EHF (IS) | 2020-05-13 | — | — | EP | claimed |
| EP-0874852-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENT WITH TRICYCLIC SUBSTITUENTS | PHARMACIA & UPJOHN COMPANY (US) | 1998-11-04 | — | — | EP | claimed |
| EP-0856002-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1998-08-05 | — | — | EP | claimed |
| EP-0665858-B1 | PROCESS FOR PREPARING ALIPHATIC POLYESTERS | SHELL INT RESEARCH (NL) | 1998-01-21 | — | — | EP | claimed |
| WO-1997019089-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENT WITH TRICYCLIC SUBSTITUENTS | PHARMACIA & UPJOHN COMPANY (US) | 1997-05-29 | — | — | WO | claimed |
| WO-1997009328-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-13 | — | — | WO | claimed |
| EP-0745065-A1 | 9-(SUBSTITUTED AMINO)-ALPHA-6-DEOXY-5-OXY TETRACYCLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | PFIZER INC. (US) | 1996-12-04 | — | — | EP | claimed |
| WO-1995022529-A1 | 9-(SUBSTITUTED AMINO)-ALPHA-6-DEOXY-5-OXY TETRACYCLINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | PFIZER INC. (US) | 1995-08-24 | — | — | WO | claimed |
| US-5202266-A | 25-hydroxy vitamin D3 derivatives, process for their production, and assay method using the same | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1993-04-13 | — | — | US | claimed |
| US-5095126-A | Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1992-03-10 | — | — | US | claimed |
| US-4092474-A | Cephalosporins having a metaloxy group in 3-substituent | SHIONOGI & CO., LTD. (JA) | 1978-05-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106349-A1 | Compounds | CFTR, AQP1, CTSA | TSHR 4630/4885ALDH1A1 1837/4885SMN1; SMN2 3146/4885 |
| US-20230140861-A1 | CROSSLINKING LIGAND, METHOD FOR PATTERNING NANOPARTICLE LAYER, QUANTUM DOT LIGHT-EMITTING DEVICE, AND DISPLAY DEVICE | PDCD1LG2, CD274, L1CAM | TSHR 2390/4885ALDH1A1 586/4885SMN1; SMN2 3868/4885 |
| US-11236120-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | CFTR, AQP1, CTSA | TSHR 4168/4885ALDH1A1 2483/4885SMN1; SMN2 3481/4885 |
| US-20200317710-A1 | Azithromycin Derivatives With Epithelial Barrier Enhancement Properties | CFTR, AQP1, CTSA | TSHR 4168/4885ALDH1A1 2483/4885SMN1; SMN2 3481/4885 |
| US-10723752-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | CFTR, AQP1, CTSA | TSHR 4168/4885ALDH1A1 2483/4885SMN1; SMN2 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.